

AMENDMENT

In the Claims

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-40 (Canceled)

41. (Previously presented) A fusion protein comprising an immunogenic polypeptide, wherein the immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8).

42. (Previously presented) The fusion protein of claim 41 linked to a suitable carrier.

43. (Currently amended) The fusion protein of claim 42, wherein the fusion protein is linked to the carrier using a disulfide/amide-forming agent.

44. (Currently amended) The fusion protein of claim 42, wherein the fusion protein is linked to the carrier using a thio-ether-forming agent.

45-51. (Canceled)

52. (Previously presented) An immunogenic composition comprising a pharmaceutically acceptable carrier and the fusion protein of claim 41.

53. (Cancelled)

54. (Canceled)

55. (Previously presented) The fusion protein of claim 42, wherein the carrier is diphtheria toxoid.

56. (Canceled)

57. (Canceled)

58. (Previously presented) The immunogenic composition of claim 52, further comprising an adjuvant.